Dear Healthcare Provider,

The Food and Drug Administration (FDA) has required this safety notice as part of the LEMTRADA REMS (Risk Evaluation and Mitigation Strategy) to highlight new risk information about stroke for LEMTRADA.

The goals of the LEMTRADA REMS have been modified to reflect the following new safety risk added to the BOXED WARNING of the Prescribing Information:

Serious and life-threatening stroke has been reported within 3 days of LEMTRADA administration. Instruct patients to seek immediate medical attention if symptoms of stroke occur.

LEMTTRADE REMS Goals

- Informing patients about the serious risks of LEMTRADA, and the need for baseline and periodic monitoring
- Informing healthcare providers about the serious risks of autoimmune conditions, infusion reactions, stroke, and malignancies with LEMTRADA, the need to counsel patients, and the need for baseline and periodic monitoring

LEMTTRADE REMS Requirements

- **Prescribers** must be enrolled in the LEMTRADA REMS
- **Healthcare Facilities and Pharmacies** must be enrolled in the LEMTRADA REMS
- **Patients** must be enrolled and authorized in the LEMTRADA REMS

Reporting Adverse Events

Report all suspected adverse events to Genzyme at 1-800-745-4447 (option 2) or the FDA at 1-800-FDA-1088 (1-800-332-1088) or www.fda.gov/medwatch.

This letter does not contain the complete safety profile for LEMTRADA. Please see the enclosed Prescribing Information.

If you have any questions about the LEMTRADA REMS, please call 1-855-676-6326 for more information or visit www.LemtradaREMS.com.

Sincerely,

LEMTTRADE REMS
LEMTRADA REMS DESKTOP
PUBLIC and Prescriber Desktop Pages Only
PUBLIC FACING PAGES